Title

Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.

Document Type

Article

Publication Date

11-1-2022

Publication Title

EJHaem

Keywords

washington; swedish; swedish cancer

Abstract

There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti-BCMA-targeted chimeric antigen receptor-T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA-antibody-drug conjugate therapy. We observe that X-containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients' prior anti-BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X-based regimens following broader anti-BCMA therapy.

Clinical Institute

Cancer

Department

Oncology

Link to Full Text

PSJH Full Text

Share

COinS